ArticleInfection and drug resistance2025
Clinical Features and Outcomes of Pediatric Intraspinal Paragonimiasis.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Central nervous system infection is the most common and severe clinical subtype of ectopic paragonimiasis. Intraspinal paragonimiasis is rarely reported. This study aimed to provide experience for diagnosis and treatment strategies of pediatric intraspinal paragonimiasis. Methods: We performed a retrospective clinical analysis of patients hospitalized for intraspinal paragonimiasis between January 1, 2015, and December 31, 2021. Results: Nine patients were included. The median age was 9 years. Clinical symptoms mainly included weakness (9/9), sensory disturbances (6/9), urinary retention (2/9), fever (4/9), chest pain (3/9), cough (2/9), dyspnea (2/9) and subcutaneous nodules (1/9). Spinal magnetic resonance imaging revealed intraspinal extradural enhancing lesions in the thoracic spine in 8 patients and isolated cervical spinal cord lesions in 1 patient. Seven extradural lesions were connected with the pleural lesion and subcutaneous nodes. All patients received praziquantel without undergoing spinal surgery. After a median follow-up of 36 months, two patients had sequelae of mild weakness and urinary urgency, and seven patients recovered completely after a median time of 13 weeks of initial praziquantel treatment. Conclusion: Pediatric intraspinal paragonimiasis mainly involves the thoracic segment of the spine. Weakness is the most common manifestation, and some patients may develop sensory disturbances and sphincter dysfunction. Most patients can recover completely with praziquantel treatment. Lesion resection is no longer a necessary treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.